Exactly! This quote is entirely wrong: ""In the five years from 1998 through 2002 [...] 415 new drugs were approved -- an average of 83 per year. Of those, 133 (32 percent) were new molecular entities. The others were variations of old drugs. And of those 133, only 58 were priority review drugs. That averages out to no more than 12 innovative drugs per year, or 14 percent of the total.""

Just because it didn't get priority review, doesn't mean it's not innovative.

It just shows how little Angell understands the industry.